A Phase 2 interventional study of Surlorian and Placebo in Autosomal Dominant RYR1-Related Myopathy, sponsored by RyCarma Therapeutics, Inc.. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by RyCarma Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Muscular Diseases with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Muscular Diseases · France.
Among the 35 studies in Muscular Diseases with a site in France, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 7 of the 13 other live ones, and was the 33rd registered.
232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.
Browse Muscular Diseases studies →10 of the 35 studies in Muscular Diseases with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
AstraZeneca · Sites in France, United States, Argentina and 32 more countries
Ages 5–80
Hospices Civils de Lyon · Sites in France
Ages 2+
AstraZeneca · Sites in France, United States, Canada and 7 more countries
Ages 18–70
Pharming Technologies B.V. · Sites in France, United States, Australia and 8 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12
First in 2010; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 28 is below the median of 38 across 134 interventional studies indexed under Muscular Diseases.
Median enrollment 55 across the 27 interventional studies, 129 across the 8 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 35 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with RyCarma Therapeutics, Inc. as lead sponsor.
RyCarma Therapeutics, Inc. has 1 study filed under Muscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07560020RyCarma Therapeutics, Inc.A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy | 2027-08-27 |
| NCT05650229Pharming Technologies B.V.Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 35 studies in Muscular Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is testing a medicine called surlorian in adults who have a genetic muscle condition known as autosomal dominant RYR1-related myopathy (RYR1-RM). The goal is to find out whether surlorian improves muscle weakness, and whether it is safe and well tolerated.
The study is taking place at several medical centers with doctors who specialize in treating people with RYR1-RM. Everyone in the study will receive both surlorian and a placebo (a "dummy" treatment) at different times, but neither the participants nor the study staff will know which one they are getting during each period.
During Treatment period 1, participants will be randomly assigned to receive either surlorian or a placebo, which will be followed up by a washout period. Following the washout, in Treatment period 2, participants will switch and receive the opposite treatment from what they received in the first period. This main part of the study lasts about 16 weeks.
After finishing the main, placebo-controlled part of the study participants may be able to join an open-label extension lasting approximately 12 months. In this extension, everyone receives surlorian.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Surlorian
Other: Placebo
300 mg administered once a day
Also known as: ARM210 (S48168)
administered once a day
Change from baseline in the 1-minute sit-to-stand test (1-MSST)
Time frame: Day 1 to day 28 [approximately]
Change from baseline in the 6-Minute Walk Test (6-MNWT)
Time frame: Day 1 to day 28 [approximately]
Change from baseline in the Timed Up and Go Test (TUG)
Time frame: Day 1 to day 28 [approximately]
Change from baseline in the 4-Stair Climb Test (4-SCT)
Time frame: Day 1 to day 28 [approximately]
Change from baseline Quantitative Muscle Assessment (QMA)
Time frame: Day 1 to day 28 [approximately]
Change from baseline Manual Muscle Testing (MMT)
Time frame: Day 1 to day 28 [approximately]
Change from baseline in Patient-Reported Outcomes Measurement Information System-fatigue (PROMIS-F)
Time frame: Day 1 to day 28 [approximately]
Change from baseline in Patient-Reported Outcomes Measurement Information System-physical fatigue (PROMIS-PF)
Time frame: Day 1 to day 28 [approximately]
Chage in International Physical Activity Questionnaire (IPAQ)
Time frame: Day 1 to day 28 [approximately]
Number of Adverse Events
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in systolic blood pressure
Systolic blood pressure will be measured in millimeters of mercury (mmHg)
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in diastolic blood pressure
Diastolic blood pressure will be measured in millimeters of mercury (mmHg)
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in temperature
Temperature will be measured in degrees Centigrade (°C)
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in hemoglobin
Hemoglobin concentration will be measured in grams per liter (g/L) using standard hematology laboratory methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in white blood cell count
White blood cell count will be measured in ×10⁹/L using standard hematology laboratory methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in platelet count
Platelet count will be measured in ×10⁹/L using standard hematology laboratory methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in serum creatinine
Serum creatinine will be measured in micromoles per liter (µmol/L) using standard clinical chemistry methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in estimated glomerular filtration rate
Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in serum glucose
Serum glucose concentration will be measured in millimoles per liter (mmol/L) using standard clinical chemistry methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in QTc interval
Corrected QT interval (QTcF) will be measured in milliseconds using triplicate 12-lead electrocardiograms
Time frame: Day 1 to end of study [approximately 68 weeks]
Change from baseline in urine protein
Urine protein will be measured in milligrams per liter (mg/L) using standard urinalysis methods
Time frame: Day 1 to end of study [approximately 68 weeks]
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Aug 2027, 11 months after the start.
Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Surlorian